Liao Dehua, Zhang Jiwen, Yan Ting, Chen Shanshan, Li Wei, Shangguan Dangang, She Zhihua
Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
School of Pharmacy, University of South China, Hengyang, People's Republic of China.
Onco Targets Ther. 2023 Sep 5;16:731-738. doi: 10.2147/OTT.S426989. eCollection 2023.
As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.
作为一种新型的第三代间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI），劳拉替尼在携带敏感的ALK激活突变且在第一代和第二代TKI治疗中出现进展的非小细胞肺癌（NSCLC）患者中显示出优异的全身和颅内活性。与其他ALK-TKI相比，劳拉替尼在高脂血症和中枢神经系统不良事件方面具有独特的安全性。劳拉替尼引起的不良事件耐受性良好，很少有永久停药的报道，剂量调整和/或标准药物治疗对不良事件的管理有效。我们目前的研究回顾了劳拉替尼的安全性概况以及相关管理策略。我们目前的研究旨在为劳拉替尼的科学管理和应用提供实用指南。
